<SEC-DOCUMENT>0001571049-14-007125.txt : 20141209
<SEC-HEADER>0001571049-14-007125.hdr.sgml : 20141209
<ACCEPTANCE-DATETIME>20141209160147
ACCESSION NUMBER:		0001571049-14-007125
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141203
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141209
DATE AS OF CHANGE:		20141209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		141275163

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1402439_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>CURRENT
REPORT</B></FONT>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Date of
Report (Date of earliest event reported): December 3, 2014</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>Applied
DNA Sciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware</B></FONT><BR>
<FONT STYLE="font-weight: normal">(State or other jurisdiction</FONT><BR>
<FONT STYLE="font-weight: normal">of incorporation)</FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>001-36745</B></FONT><BR>
<FONT STYLE="font-weight: normal">(Commission File Number)</FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>59-2262718</B></FONT><BR>
<FONT STYLE="font-weight: normal">(IRS Employer</FONT><BR>
<FONT STYLE="font-weight: normal">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>50 Health Sciences Drive</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stony Brook, New York 11790</B></FONT><BR>
<FONT STYLE="font-weight: normal">(Address of principal executive offices; zip code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Registrant&rsquo;s
telephone number, including area code:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>N/A</B></FONT><BR>
<FONT STYLE="font-weight: normal">(Former name or former address, if changed since last report)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: normal 10pt Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-weight: normal">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: normal 10pt Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-weight: normal">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: normal 10pt Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-weight: normal">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d 2(b))</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: normal 10pt Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-weight: normal">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 3, 2014, the Board of Directors of Applied DNA Sciences,
Inc. (the &ldquo;Company&rdquo;) elected Joseph D. Ceccoli as a new member of the Company&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Since
2010, </FONT>Mr. Ceccoli has been the Founder, President and CEO of Biocogent, LLC, a bioscience company located at the Stony Brook
Long Island High Technology Incubator. Biocogent is focused on the invention, development and commercialization of skin-active
molecules and treatment products used in regulated (OTC / Med-care), personal care and consumer products. Prior to starting Biocogent,
Mr. Ceccoli was Global Director of Operations for BASF Corporation, a global Fortune 100 company and the world&rsquo;s largest
global chemical company, where he was responsible for the integration, operations and growth of domestic and overseas business
units from 2007 to 2008. Prior to BASF, Mr. Ceccoli was a General Manager for Engelhard Corporation, a US based Fortune 500 company
and chief operating officer of the Long Island based Collaborative Group from 2004 to 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Ceccoli holds a Bachelor of Science Degree in Biotechnology
from Rochester Institute of Technology and advanced professional training in various pharmaceutical sciences, emulsion chemistry,
engineering and management disciplines. He is a member of numerous professional organizations such as the American Chemical Society
and the Society of Cosmetic Chemists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As has been the policy with other non-employee
directors, Mr. Ceccoli will be granted annually a five year stock option, fully vested after one year, to purchase a number of
shares of common stock having a fair value of $60,000 as determined using the Black Scholes value or as determined by the Compensation
Committee of the Board. In addition, Mr. Ceccoli will be a party to the Company&rsquo;s standard form of indemnification agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no understanding or arrangement
between Mr. Ceccoli and any other person or persons with respect to his election as director and there are no family relationships
between Mr. Ceccoli and any other director or executive officer or person nominated or chosen to become a director or executive
officer. There have been no transactions, nor are there any currently proposed transactions, to which the Company was or is to
be a party in which Mr. Ceccoli or any member of his immediate family had, or will have, a direct or indirect material interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the press release issued by the
Company on December 9, 2014 related to Mr. Ceccoli&rsquo;s election to the Board is furnished as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01. Financial Statements and
Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;&nbsp;&nbsp;<I>(d) Exhibits </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD>
<TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release dated December 9, 2014.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:&nbsp;&nbsp;December 9, 2014</FONT></TD>
    <TD COLSPAN="3" NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="3" NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-decoration: none; border-bottom: Black 1pt solid">&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD NOWRAP>&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="height: 0px">
    <TD NOWRAP STYLE="width: 50%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 5%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 42%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>Exhibit
                                         No.</B></FONT></P></TD>
    <TD STYLE="width: 3%"></TD>
    <TD STYLE="width: 81%; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release dated December 9, 2014.</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1402439_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">PRESS RELEASE</FONT></TD>
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">For Immediate
    Release</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">December 9, 2014</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Contact:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Media Relations</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">631-240-8800</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Applied DNA Sciences</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>Applied DNA Sciences
Elects</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>Joseph Ceccoli
to Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>STONY BROOK, NY, December 8, 2014</B>.
<B><U>Applied DNA Sciences, Inc</U></B>. (NASDAQ:APDN), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology
and product authentication solutions, has elected Joseph Ceccoli, Founder, President and CEO of Biocogent, LLC, as a member of
the company's Board of Directors. Biocogent is a bioscience company, focused on the invention, development and commercialization
of skin-active molecules and treatment, and consumer products sold globally in 15 countries.&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Prior to founding Biocogent, Joe was
Global Director of Operations for BASF Corporation, the world's largest global chemical company, where he was responsible for
the integration, operations and growth of domestic and overseas business units.&nbsp; Earlier, Joe was a General Manager for Engelhard
Corporation, a US-based Fortune 500 company.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">These senior positions followed a successful
19-year career as entrepreneur and Chief Operating Officer of the Long Island-based Collaborative Group. Beginning as a start
up in 1986, Collaborative developed into an employer of nearly 300 professionals and skilled workers at its research and manufacturing
centers.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Joe holds a Bachelor of Science degree
in Biotechnology from the Rochester Institute of Technology and has received advanced professional training in various pharmaceutical
sciences, emulsion chemistry, engineering and management disciplines. He is a member of numerous professional organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Joe lives on Long Island with his wife
Stephanie and two sons.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&quot;Joe's professional career has
always been focused on the growth of businesses and job creation on Long Island,&quot; commented Dr. James A. Hayward, CEO and
President, Applied DNA Sciences.&nbsp; &quot;He is a pioneer in helping transform small, growing companies into significant enterprises.
Joe's extensive operational experience will be helpful as the business continues to expand. Add to this a strong science resume;
we are confident he will further strengthen our Board's breadth of talent and background. I know he will make an important and
positive impact on the company.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Ceccoli stated, &quot;I am delighted
to have the opportunity to join the Applied DNA Sciences Board of Directors. The company's strategic vision and unique deployment
of science to the ever-demanding world-wide need for security and authentication solutions makes it a global leader.&nbsp; I look
forward to participating and working with the Board to further the company's strategic and operational goals.&quot;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>About Applied DNA Sciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">APDN is a provider of botanical-DNA
based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature&reg; DNA describes
the uncopyable marker that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of
a family of products such as DNAnet&reg;, our anti-theft product, SigNature&reg; T, targeted toward textiles, and digitalDNA&reg;,
providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">The statements made by APDN may be forward-looking
in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could
differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance,
market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual
Report on Form 10-K filed on December 20, 2013 (amended on May 1, 2014) and our subsequent quarterly reports on Form 10-Q/A (for
the quarterly period ended December 31, 2013) and Form 10-Q for the quarterly periods ended March 31, 2014 and June 30, 2014.
APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances
after the date hereof to reflect the occurrence of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>media contact</B> Mitchell
        Miller, 631-240-8818 &nbsp;<B><U>mitchell.miller@adnas.com</U></B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>investor contact</B>&nbsp;
        Debbie Bailey, 631-240-8817 &nbsp;<B><U>debbie.bailey@adnas,com</U></B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>web</B> <U>www.adnas.com</U></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>twitter </B>@APDN, @APDNInvestor.&nbsp;
&nbsp;&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```(Q```'?8``":J```Q`/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`*P%T`P$1
M``(1`0,1`?_$`0L``0`#`0$!`0$````````````'"`D&!0,*!`$!`0`#`0$!
M``````````````$$!08"`P<0``$$`@(``P8%!0````````4#!`8'`@@``3`4
M%2!`4!(3%A!@-#87$3$C-Q@1``("`0,"!`,$!@8%#0````(#`00%$1(&`!,A
M,10'02(543(C%B!Q@4)2,Q`P86(D-%#10W4(8[.4M-0E-94F=I87&!(``0,!
M!`0*!0P#`````````0`"`Q$A,1($47&2$T!!88&1H=$R%#3PL>$B!1`P4&#!
M\5)B(S-S)$)R1!,!`0`"`@$#`@4%`0$``````1$`(3%!41!A<2"!,/"1H<%0
ML='A\4!@_]H`#`,!``(1`Q$```'?P```I:3=9(LOO@%&DO(OF?3YP?T6EL)S
M.^```^)"I.`````!_,9:E-4M\:OJ``*C$"FEAD2:)D9%>2'RUOKS/OFYOKJ4
M4C,NC]%^PPJ5?H7&^G\?K[N-]K&<KT$=;77\WEX_>\-UE04MLM=K/.E^!UY-
M!4$TI3,RK,RU<+QE/33H_+%NM9[?7<W&.LS[B<5U%_NKYWI-_J.CP\FZ'`]@
M!A*=D<U5PI*=+&M6"B"ZN`E2#A:[>60I(@MNI^R?F-P>$ZZI7<<KT^OR_/R<
M?^+Z^.@Q,B*_SSM/(UV=3=-Y5QQ2D9-M60\N!7I?4U)C\_9VQ<V7^RS8*7\M
M>?AZD]IS$A;37P5Y]9]<SO);Q_OI'U_-RYHMK9;D.DZK%R<NRI:?>WY1H&8=
M^IH+YMER0;/2*"RWY*4$GER>HT%8^QYJU/$=3\?4X_88<?[77QAMM=)WYAWD
M":_-[P]9/C5>8D6WNH^Q(J527O2("Z)4VS8N7EC&VRNF?B?#H=+:#-QL]^1Z
M+>_K>=)[6+D3US.][3"RQ1`L\2>9&V:Z2@```````````````9I&5)=@V%.F
M`````````````````````,OC3%/04``?_]H`"`$!``$%`O;NBW.ZC%R>=QN%
M1X838&AWXVE<F5;R7CQQY5I74WSG8KV\\\4\(98\-L#Q%54D$[`VSKZ*9?R3
MLQ<V5,4!)X/*_:M6YHI4C2N]I8)/SJBF"29S<FOQ96!3V/V/'K4N:)5(UK[:
MF#3L_N=^VKK>PT;5H4W&PM>*;J0#%_%98"F@BR=GH-71RS;<C-M360R$9%Q6
M=^1<CAKU^U3E[Q42[B,O$309-K2C\(<1>YXM)GUD6/'ZOCM9;/QZR9585HQ*
MLA]:;$1BUSVO9:N"V-B[002O3]5;#PVU2%G6C&ZI!PS;6O965,F!\?%"=N((
M=E%IW9$*DQB&WD"DQNR;'`U?'*UVBCEBR=97!!*Q[;DMXRLG5U+N1H\G;%:N
M(ENF1;9AMFJ_/H_]"1#@B\8J9*?C$@`BTMD=I*YA@*$R:P3B^HM3T[6;6NJ@
M;)0#9"N$!=X7MM#6T)$0+8,R_D--;1_Z+V%/%!U"#B)%K&]=@-GP%IJQ`(G*
M8Y>M>1:*W#8;QS*+-D->0IS'JO4<CZEI:'1U]'*R2P!V;50<7,3UQPJ-"`-X
M0>76A7U<W(*(S23"V]H[4"('"XKUK22=AX;4C\@DV<"+!D]AW(V:RW9;<&$1
M6-C+YDADA3L3IVM8FT,F2DEO.?IR2<A;-K&SI?4D(O&/JRE\T3(,<,K`U;E<
M?M%"3,ON=_R6QR+S=`I4CROE*\V/FI0WU*B77<<GPYKT)-"CK;EI45("LMEF
MO]_6*,M6&%J_U9A]7;$AHI2]*-JN;5W!I=-+&2H2WK#*W[4IRQ8_=5?G;`K0
MS4H^8U5C4>SS)I4U-B*M8%-?[)@TAK6AI$UF,_K]G-V*L`N`RAE"FXZ!UO%R
M$1C4=A!<38DAK&1L3YNI;&E+28Q2V,(E%ZCM*3V!;^NC&PS-616]PIR@JFD-
M<-B6OEFPDW"J0GQ&62NII0;OK9"J)-:P,M3H^7U+#JPV-AYNTZ!-&Y5U2U\S
MQ>Q8E8Z8@-2%D3J8=====&08>1#YWIL(=K>C[+5!@#V?<JO3UR@@L>CPB;[(
M6/\`:T^Y]JS[C81:+)'Z9[T3\-BX1([`KJ$C'@:'\H6J9M!I]\!L?:&"0$K)
M'5N;'K5QIW'PR@D,)`LOA;_Z7\GM?TWM?__:``@!`@`!!0+Q\,?GS*CO35_@
MW?\`?V6K59XM]LO$N2G]<VC3U?!\Q7'K#@KHCB\C[UFG[@Q8KOU?M<AQT!(-
M4^,A"S_#[6?\7CCU!'P^_:%X8L@[8J03<F>L53D@(/,'ICOMP(-+K#VP`@[7
M<NT^D77CMU$DU$/3W/?E$N>10XH)>]J-^VZ.7DD>.QJN?:R"S?/QQ9/,:KB4
M`H9>H9K$BSM-\\=$4%Q34PT4:MS8EDJ[5Q7=>X].G'7$'K7Z?G1O%%,55_.C
M>>=&\S6#*=_U;_7_`"]__]H`"`$#``$%`O'R[^7$>]\\E\&Z]I==-LEZZV4X
M`_2K'&J635VD\3>DT&7;8PU<Y^X.G:3-/UYGQ`NS<9\=$4VF7K[/B1IJLI[B
M_P`LG1)<>SR0&=Y8"@[)MFU&]?1)"TDWBY=FW20;9]J-_'6P4SP5\ZCUYE3G
MFEN8$6ORK=+*=>:4XW?)X\2536Q\=^QQ>X=L"RV/D\4V0]OFU:MV2J3]P-<8
M+K"B#K!NGVBA[C]!#BS5?Y_*O>88=II>5>\\J^YBF2PZ_P`WTOR]_]H`"`$"
M`@8_`OGPS24V'%BJRNCZ-$$%KRFR-<QS@;DS^(>LH2.+&-(JMS/2O(MY'A;%
M6E2C+[KXAHX#NLO2H%;5WHND]BWK@UT8%30W=-.KY,<#X[+ZULK=Q+O1=)[$
MZ9SH\+16\]G`G_$817-%IYK2/;S(2"1[B3=6M>2BR['6BC*[11RT;RV)E*4L
MX@LMF9/W:TKS>Q093*$MA++QQ\Z\%,XR9=P-]O$I(A<UY'7P#%,W''HK3K5,
MOEYG.&AZ\GF=M>1GVE_6AE#.7M1AS\4AEK9:6G4:KR68VD/"9:5FFMJW<[2U
M_+P`FF*%PHX+Q&7R[O$<6CUFG,$W/YGB>#9H'$$[,15P&E^H*')-#M]&>2G&
MAD_BL>-C;B+_`$U+#E8"(J6N_P`ONYU),WNN<3P*F\?365_9.9WOY7V'INZU
M?G-L+&['N^4XC378K\YMA7YS;"Q2#-%W^S56CO#5T^]37]7_`/_:``@!`P(&
M/P+Y\NT(R8<-'4^C3-+W0BPAP!%Z=_)]@18`YS@5O(KE@=4R:$([6R'@.\FK
M2M+%=)T>U;L8@\F@J+_DPRM?R76]:[LG0.U")H?5QT>W@3<E+9EP[IL186-:
M*7Z%,X7^]ZD)WMQ/=IUE3P,_;T<ZES.8&*7%<>)>)B&"8$76)DAO+1P"D3L+
M]556::,`_E7F8=E>:BZ%^M)'BY.Q"7*2,W>JO0O,P[*/B9XW:*6+'$0YO``*
MX9&W%;F:8;GTY$<I!^$CI389*8AVJ3-&F[>.?B1S/P]^%SKPL4\H,GX>+TYD
MR)W>:T#@7<;74%^AN-WRMM]O4O\`FV5A&''JH/M5V6V2KLMLJC#`!J*O;OZ<
MU?J__]H`"`$!`08_`OT\'D8P?UV<SDRQO8]?Z#LR*H9W.YZ6UNUUT\N@Y+RK
M(+Q6.,JZH*18]C+%GQ"NA*0)KV;8F=!C[HS/PZI9;%VE7<=D*ZK=.VF=RGUW
M#!K8$_80S^APCCT8",M^<;PT_4^OFGZ&2NTZ>_9Z2Q#_`/-Z^8^7]%JUMW^G
M0U^S73=V@D]NOCIKIU>R1X^,=Z3)-H0J']_>()2Z&26P-)T=I^S^H)AE`@`D
M9F4Z"(C&I$4_"(B.LI^4\TG+?1[7I;\+!RI6<[^VT8<`2VL[MSL8.HEI_6&Y
M[5I2H2-C6F*UK`8U(S,Y@1$8^,]/H\>AO,LHHMD_3V0C$`7ANURA@R'Z1/\`
ML0,9^WK9PC!GQ/CUF3$,C63Z%/8+[IEGLC$O<0?&:@QY^71<[YCS(LSFW8]]
M1U*I-ERF3:C\3UN0ME#;HKGYACMA\_C^G39GAO7+^2ALX[&8].YMB$;8:QCV
MR%>NH)./.=?LB>JG&_0YC!97(GVL>-U2[-6V[0BA$6*A&2FR`S/S@(?WNC:R
M=JU@3#+^$`B2*?#Q\(CI^/HX7D&716>2&9!8U:BF2L]IG638;WC#PG3?"YGJ
MOR7C;7G1<9H8NT@J]FM95_-KN"=0DPF?,"(9^WJDSD$7[5[)]R<=C,<CN/L`
MDA%S2>V5U4*7OC[Q;I^$3U4XV6.S&!R.1;V,:5P%6JMI\_=KRVI)&AI_#<.S
M^]UP7_W2?_51Z];SGCS>2X1-G%?]WUW>ELC;9,@FPBSN`DD&LQ.D^(E,=8SD
M":XX'BU#C57)KJBLF1C<4%(7BJ%H$R.4I\-!B=9Z["^.\E;0ALAZ_;1`Y7NF
M(<-,K&[28\=).)ZKYSC]N;F/L"HA,DN082U"K$+8MP!,'"W#KIK'5GC3*67S
MF8HR(WU45+KUJ;"$3A3+-L@[C>V43^&)#_;U[,Y'`A=J6<?R&JG*8Z^D1;4-
MV:Q,HD7KW)L+;"RTF"U\/&(Z=E\LTU5$;1GMK-K#8?@M0",?>,OMTCJY0;0R
M=%-FK92FZV%-"#-1B'>2DB8`S/\`#OZS4_#\POG]GH:73Z5>IDLDVM8=7>2P
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MB]8V+=GT="E03#;-RSL)L@,F2TJ$%C,R1E'[9ZK8:W1S6`N7K**E$K20N5K#
M[+02I<MIR1IF2/\`>#;I\>LAFLJ_TN-QE5MRZ_8QG:0D=QEVU";#G3X1$SUB
M^-8K"\B=.6RM3%5<@Y=-"-]MXH!Y)FR3Q3!']F[3X=8\.0#DK=[*"UE+'XRN
M+6FE!`#G,:]B*Z@`CCS+=/PCJGA;N*S6!+(.76J7+`INU9L-+8I;_23+U=PY
MB(F`*/'QTZ9R3/Q::GOA4JU*2^Y8N6VP1`D)*14J-H3,D4Q$1'5;BJ^-YC$W
M;PW&4W-?5M5S"G79:+NR'9-1DI4_`HU^/37LG:M*S:PO/0%C)E.D>,Z#'3N/
M8S(OPG`*MKY55X9!/H);"YRN13!J;=>W7<I$Z"&L1.DZEU6KXG)\_P`9E4K@
M&Y&Y0QEVE<9,C)-L4AM+8B!C6!A1_KUZ(."<OR=W"(\4UK&T*LK`M?GPU]MN
MFK6/B!:S'V=!4YYQ95F!*0=D<`ST]@=/#4L=:,T-+7^%JXZ:_%U.0OA/\U<T
M:ZVA$!+"F8.Y`SM&/A,]?^%\B_Z)4_[=U1Q2*&=4_(65U4F^K7A4-;.T-\A;
M,H&9_L_0]S6\Z`,L'#'LJ8#!W#W4BKU;9X]32IG.CE5UK@Y'3MRQVXO'3JOS
M;`XW'\7Y)A<QCAHVL.I>-*W+FD7:E56%K9840=T#TWCLGQZQ>8F\^<IEU5.,
M7+^\RM.2%VS3MFQTR)]RW7HR+"\=T'/V]<?_`/3>%SIYK"4KF1RF1H5[=F^V
MXB'LGNN$S2L#9,`(S&SKG/MSQAKCXB_&,O31EYV5T+2$X^R&AE):%5.Z:)F?
MFGPB9\.N1Y7GU6,@&#PE<\5@+TZTM:Y5ZNXJ93M=77)$R0TV2;=2ZGF>&QE'
MC/(\#D<;]-N89:<6=J7V`7Z8@KPJ&M2,=U91^(';G2=->O93.909'(Y2QC[E
MS6)B9>[%I(STGQ_$\_V]6/\`>&`_YV>O:K#4Y:NCGJ6+C*,7,B+%X[$U7UZ;
M=--5N<WN:?&51TCC@_\`"6RWCRIK4VVVI?9D;A2F`*_.3^B>KBRS[T'!ZC\.
MO<W+V\!DL-@0XS?R6+Q.5[LM;G::6V,=Z:H6C#[=>)!Q[!D_ECK,\]Y11I<G
MY1D^09!5EV94K(S1V;3+15GNP-FV3R,CF-TC,1Y=>U%CB>/3C+'(L_C"OXJB
M(+IBRIF\="KB:JX_P\V(<4'IH'X>L1KKUB.$95K*W'J^2J;=I$H+4V:%5[`D
MM($V[YE83XR/<ZNTRPN+QZZU)YHO(KJKOI$M9'%CU(0+)VE&I;IF"^/7.+E<
MS4T79EE5P3H0RO%5@%H%KX$)1U]8R&+JY&YD`:IQ7@"V$`%RXJ>VIL$*Y8(1
MK.FLZ=<]P5#5>/6BQ834W:C$HM*[$#$#MT2-F1CQUB)^/7+N2<DKJR>53DX!
M=2]M>%,#)NV2KGN7,A"H`-==NWIG*L345ALS3N4>R6/GTBWR3YUCTZ]JN[&_
M?O&-_P`OV=<"SW&DJRN4PLT\U;P-@P[65BQ33W2%;ME>PY+0^X6W<!EIX^$X
M3B//?:]'!.:?B)PE^,<M">Z=<E=I,OKIN5/5+&5QM)@%Y:]6>,<RN/\`HE*_
M&/JXPK'8W4Z6(F\NF@A,96-ZT.XMOSEW/U=/L\<XO@\+9]"VI-G'8ZM6LG7^
M_P!D["PAS`DXU\9GQZ]\LK07WKV.LV[M17\=BM2RK4CY3YF/63Y"?LA;]V,G
M<S++!<CN>LO5Z]C;!L1V(QUU!V2:^6&93NF9C[.N&\BXE[*7_;++T,HD[MVO
M%C'XBXCOIDF70;1HUTPM6\3VZ]T"TD9Z]M.(<@7ZS`IQ]1Q8^9.4N.VZXYT,
M#Y1[;SI`):3XC'7#LYQ["8_!WSR-C'M+%5DT0>@*L/3+EUP`3:@T_(7G$3/7
MLWC777UZO,0P'YAO[XVO@,;49MLF101;G'WI\?&0\9ZQ8XCBF%.SCXKO1F+%
M-%O)MLJ^<+LWG";>])SNB8F('X=<YR&4]NKON@[%V;V.I\<AEV$8RE1L12KO
M8BK7LR:@"-=ND!W&;N@QE/\`X9KO$\G6.O\`3,YA:=RBVC*S'\)P+Q-5-BNQ
M?RZ,*-OWHF)CKVR,THRW+>'A5N9GCS'"T<GM5"D[V.;`V;U>L`BX9/\`$DCT
MF9TZH8#W)]LJ_M]RFHEWTO(_386@(-+`<M8MJINTPL+^6-I-`OC,=7*+9F%7
M:KZID$S!0%A1**1F)B=8@NLO3;C46L'FVK16SC:";*<A3KG+$.IN."%-I8,_
M$04C.Z/LT+I-K'^Z7!@)R8:="[Q^*N0K1KM(+-1GSA(GX:^(S\)Z\?<K@>G^
MX1\NFJY%RKVVM-8OMQD$\?BIE$QYQV<A6[5D-)^&[3K\U^VON?B+V2Q^]PX]
M3&5<@:H'4E5Y8!U,AW/+M,@8*/MZK\8YIE,'Q]K8(`S>1X^A0Q8G\12<A76M
M4)[T%H)Q$1Y:Q\>HF/<W@L$,ZQ,8.(F)^V)^$]6OS+SWCF4WRKTGH:Q4^S$0
M7=[GGOW>'4W,/?KY"M#)43JY[Q%@Z3(%]A1K_0KW)]J^1AQ/F?;[61%I,52R
MD0,!WI8I5B!::QB&+8HU-VQ,Z3&LR[FW/,3?NT'!](PD'(8V8.2BQ9>RI3JU
MT.$?NSVG&4>&L=8?BF;.H>2QO):_?*DTW5I]3?RUI?;88*(OPW1K\L>/6"3[
M?>XV.'C&:P]3(IKW_P`!^(+)5UV7I2+\?DC4`$V=I)9X^>T9ZR>3RF2^O\SS
M^IYK.GW)$0WDZ:U0GSZC832WM86AM+STTB(Y78X9R<>*\FX[43D*%B.\2+<M
M8"9JOL+C5:C&/'<IHSY3'QZQ9>]?.:M_C>)<-B,+B6?B7F#I!"45:6.J5^^'
M@3OG;`S,#`ZZ]<2PW$HQ=0>/Y4;!*NN.JA=(*PH4M';2[79LTT\.F\2P94@R
MAV\4Z"NO)-;94/5NK!6POU>'6(]ON3S"K./Q&+2O(4]K3QV6Q]4$Q;J2P1A@
MZ[A*)TWK*8\//H^)4/="A^5X":=?(,L,#(!0T(8"&?3FY1);)TT%\[?@75\!
MR>0Y#ELR%>,MD<HR2`^VK1B*E62,456.,RG6386L013I'63S?L;S%&&QV;?+
M;G'\E,"FM\V^`5+JUZM:4!$6R2`&`/AK/0>Y7NSR4.5\NKAIC*R)8=#&LT-8
M/[A+K`PE).>VH%`I9%)?-.D](@;$XS+47>HQ^24&Z0.8""6Z(D")9PL?&)W#
M,1/]DQA,YS*G&$*`78-1$U[4#X;?DIU[%F=(\88R(+XSU=X?@H$>[B[=13;4
MS^-;M`6^U9*(F=6-+6=(^6/"(\.JN(R3*S+*>]NFJ;#5^);LOC0F"$_=='PC
MKDO*GNI%C,PAH5U+<\K@L)M4AEJR7"8#:LOWIF/#JWR;V[S88BWD28S(4+!:
M5V,9\QRF.R])PQGS;61\I3X3T=O/\KJ6<C!#Z;%ZN^G`,>1$:UK4IP"T_NJ/
M7^+QZX;3]N.0XW#9SCZ4IRJK<P5')J&LM4ICNT[2R$6AK\PC.GE,=8#GOO'F
M,*S\I?/@\1A`#2;,3)@QQK4L%@#X%GWF24QIX=#S'C^9;Q?F*$I[=Q0GZ:W;
MJ&$T[-DDD-A%A*QVPQ?S>7GIU>_^R.8X[D/'IQ%BM2178LW_`%"6(BO8.?I5
M1^D($]=3GQGKF]?E$XQZ^294+59=)YV1*KMM"P+$,2J!DH?IIX]9#(^R7.@P
M>'R%@[L\>R#V"E%AFX)2`,JW:-I*ULG83!@QB(\](GK'\X]X^:'G[V',68K!
M8U[!QJVK.&)*Q`)J5NTML0?;6OYR&-Q3UQ+W)JMQ8\>P=*DBTMMEPY`F(F_W
M.U7A!**/\0.GS1UQW'\99C0?C,LVW9^I665@[+*C$Q($"7;I@Y\NL![><H(5
M7L/A<6BODZ7XTX[,8^D-;U=7N0'=5/S"0SMWKF8\.L!0CW%QF3X1B\C2&Q68
MTCLMPBFK[]457<6UZRFO$B(B_P"7X%'1>X/MER@^(<LM*%&5'N/KU<A$#"_4
MP^J)M6\E#$&)"8'MB?"?.IC_`'3]QE*XO4:ICZ6"=MLY&%^$P7IJ5%4D8_O-
MD]L^,#KUQ>M[.YZGQ\^._P"%;C<C(LIY#'`A:D*:5BK=[C%2KSG29W3\VO5#
ME7OAE\-;K86F^OC,1A8""(W%)1W3172I:EG\VNYAE(Q'V]1$>$1X1^J.GXK.
MXVGE<=9':ZI>0#TEKX:[3B=IQ\"C28Z9DO;O.,X_:W2U6*RA.L8\6?NQ6OJW
MWZ@[OXH=IUV)P.-YK@ZHZ+;]*J\FK0$1K);UKK9]0CY?B:1U%#E/&^)\=,6$
MNQ:_*[K2D2$S$PVJMGK`(2C28@2Z+/IY)[3YJ3`O18C$X*R[+VGP.HI*HSMG
M2C6?F-VP1ZJ\BKX3#X3'X==$+=M%(Z^$K)H-.PJNT@`BNWK33F-L?N^>D1KU
M_+]L_P#X_:_U=?R_;/\`\@M=>GHW.`4DQK,*JXG((5$SYE"US`:S^KKM^IQO
MY@]+IZKT[_IGJ_X^QW._V?V_ZOZ3X_Q:F%[*3F<;<[#+5:F/8KQ9[I=VTQ2M
M8[D>&NO7%\3D%PJ]C<#BZ-Q0F#179K4U*<$,7,@<"8^<>$_T<QSO(\34Q^,R
MV-17HLK9"E;AC0L0PH[5=DM7\OC\PQX_Z"O<>55R?(<]CS[%JK06*:E>SM$N
MRV[8F!(A@O'MB>GEY]+'$^V&(Q.,-BS#-?2EUWP`EKM?RK)`@W*UC605`R6G
ME/5?)\_R/YCNKD&1AJ7<KX8#CQVV6EMM7QB?A^$/Z^EXW"8VCB<>J2)=+'5D
MU*P$<[C(4H$`W%/G/^C,SI_^=^[ZZKW/K/KOSY_(7M]7W/\`!?4-/+M_NZ:]
M(_D?RE_Y7_+?=C^1_P`E_#_9^G__V@`(`0$#`3\A^LHX,M(OPH3/.'B:]%M1
MYI1&"SCA+++-]PV=_1!@&_$$83-OOPX.L_BRXV.CLUCA)3K(GE03FN_P`U?`
M;F&ERO1@"E3$T=WQ0L?Q'>)>.`SRJ`&:>3I8Z,^HI-9&&9-90+:"5#CX^AM&
MP)U`&T^LPHJ71"82N[BH64U4K14=1-H99?5"B)@4.=9KDW[H8>\`'!CX<S#@
M^XB3<+-A!`3+N--H]J%V$*'XD*UQMCT60/;TV#@-8'@"XT4K0[V<*#@RW%4@
M]#LQI-XNL4F,=LQJW(,KG00(<;=LK6-ZQL]Q#.-^)0V;N^]@H]'76%#VAB+T
M0@0P7+07B;QGR&]R7],9JX<I4@+X!<4AO'-`&CQ-?-,-3ME*201[J!O&0#\A
M^9G3H-IGWVRDR$,()6"C,7%Z.H@#';O-&J3+2'78CI9G%<Q<6A%6L!-YQ[8T
M<5*S@/8F5$F9XR*&SDIH<G%+E+#BGW8#/ID4R9VS`UH,N#?Q]R?:@!VUG)'(
M:QQH-*,;*ISFZH#'V#"A'1NBNE-ILR,7N18@="GL&\=CASY5LH#P,$>19@YT
M$L.(QIYI#IQC0L-X@6"J8PJT$V!@,@A(\SL`(.C,=?Z'1+[R$3EK&_W`NT2`
M-]D,J26%IA3N\SB^@+>,5[[=)Y%/HT_$-;P8^:%*6?8Q1]3$5L@4SLS)N)BR
M$`^66'23CJG]&2&\HI*?C@4796DY:C^40#$IU'G6!&ZT"G5AFJ49*&A.H#3I
MY[]!A!_SQ%>R21;K*$<S%X/9^)4#)1P3`1I5D`;D@"50!\,GSQIINIE3=U,%
M@KH*NAE4/L0+8)4ER9(F?4)@G%ZN`8.L9*"W3L2^,G,4.V,:C@BN)?+FLKB0
M\D-.=>Q55)P#GG#HRF$(W*Q#TUVP[A@*<BEB\:M,G=MK"7M5SLC%S0/M!6'5
M+XU'2H-C4BQ,!EVV)O#)B8CR"Z<.)R>YRBB'0R7#9:<H:.WDY9F72!D+G6NT
M84\F0'Z709U=0[PC[S0&CDZP/FQ\D1(G+S!0U`,?W$<YU.PD/NS(\*])]QX1
M"0`<*J@RV'E'=#PE/':UCIU[LP$!P8(FBV1QF["V^D(N7A91R@,H@B*AP%!%
M4(J)*'#1J3%[TN44[C^3V.';O$;5OQ>O->L$?'39CDHO^0YT)D--P@<*K]#1
MA<-V-:F'@-$*T02!CY]&XTY[),TX1L6A<+F`YPNRCQC393:J0W$*R(UVP\2K
M.S:W':.L>6,+PAB!F.\B-(>!PE?P<=:\:2+C'JT8;JT358<`$Z3>&5&`UN/,
M>VYHU0;P-1"-@)AHMTL='3_"4GS4[-QXW=D0)96%Y<>/VXAX>?%VJ'C6]!`,
M0CI;:BHWM01RQPJDS\16DANMLSBF=Z.72-@A$#&E/WYEFYG=><?=1C0@]MB4
M&EQ4DVMR8SG1I2T"6GU-J"08*-#DE19CUXM@&DVL0Y\H$H>VH;IM\`M54]9K
M8&D3.&A^"P*(/QU=Y!!B9LH`QAWC7B/,`+N%@*L%_0%![U*!JE(H#/776ZEU
MF-X)L*/PVEP-BSC(N;8&5Z=Y`H::,[3EZ&T+B4XH^1^.%/7I<"%B4HY7`@J8
M1<NU@A8FW;SLQ-@D?M2N-T%"L!```<`0#X,98HIH8["\E[$R*NA?%-B;5?3%
M,/=5`!&GZ.8FX6J)VZZH1J<9!JF-W7VAL#;=9(2,F\^S8ND.Q[YM=]O6NF?E
M_P#C+,%Q9O#-R\L_*U#X9J;W<]0^?KP=M_QV.L9IZ$%F<RK#3C8QC-*6/6J7
M-M%>9^HC2/R?Z%5\]&(:V>=5:3!P3Q?DTO@F&R)H`NB]>.1"S87)=5TLT*NP
MK_3/[9T/]RGY>?D(_-_!]?\`_]H`"`$"`P$_(?P$C].O3J"!^N=$=<TJDY?'
M]-":/*83M?C-=$J:=]+I^\PZ<L,9A57?L>WOG.E**HGG_N(V#L.SH#??MEIA
MU5$/*,_:_AS<^I=NU*@'_4.,96^50S:GJ>2G[O1CN@!%7`\=RZ4\ST>IFO4I
M#QI]7&7Z.\Y8\^GMZ<X<[QI8L]B;'>#N-K0W]SX(4ZPKJ@/G5^F*V555MMIX
MZS>^@ODK^NV;BK-#,Z1[KYN#:@^KY.YJ1UOSG'?;X%/VSXPRX^C[\YUZ/,RX
MY\_11%#8;^P_D;^^-I<J;9YS_M,VU7,0DX)I\B#^ADUI:$+T?J'_`#G1I^>+
MIX.S?Q/&:D-8(SS];SZNW'GZ9#VCV=)[E?9J>^(^\UH/Z7Z@\9R!5@<(:/8-
M;]W!M.MVT'E\82!0J:(--MV=8JJ<XP]]B0U5LY,,>+S]L:JAR?C+YAR\Q;OZ
MOCU=OMZ<>I#UN!`AZ_W9U<?\06-=U[>@54"CH?DV>9QZI9497:C^J9^B+'["
M7[?Y^I_^9__:``@!`P,!/R'\?OR%RC["+>AO[_T?A]3PS[WVS>U@*/78?[S]
M^P9D`>C7S_C-QX8CI'!HO+'CW7_>>(,":7Q3^9_X2FY@"J_\W@W^)@@H@.0^
M)?WGH/WU4"`<IRU[AZ2#LY"B5_$&'TN9`]M@_KT>+A8(H`'W77WKOO$?@4/P
M=X!*L8IH-7]\+50*?`3]+,&4&FS:]?L?&2MA.[?@U>[SK.53GY0_$U]$%+<H
M/Z/^<E:/;U^,ZLVJ3R"V'NX_"J?JX3)+=2SM'[YVF8FU9HT\YM_/)_X-O"OB
M^?G]L]Z;G,_0OW<X>"1>T<K\Y?);CC:?!YQ'>,*]N6IT]X)3G''VTF_#]L:U
MC6WWZX>>WSDJ%!.-'_B6JU?DXSAOZ&^YK#V?U<C-0\5OP:>_/HE_V.>WY0S]
MLFGW"/Z5L^__`,__`/_:``P#`0`"$0,1```0```",`#F8```@``````#8```
M@4D3H@FRY:G5@@'LB`"P]0`BC@T]H\X&[<CA]>!.S'E#"9`\0(5N2!**WPGO
MF#R&8!(5]I`"A````````````````"$P`````````````````````'```__:
M``@!`0,!/Q#ZWU_K.H^%[)\O#%/YQ&FK1Q'%#4DNUX$DU@$H!$^@AZ7?X*Z#
M(0R'$J)2"ELIQ=68A%=,T'K#VC:QP$.PH#%H)94$(/KG?\T-]NA(`KB:!DP:
M3B<V7GXC_CO^GDD)95#!0MJ?*15(/08I8&,3I\(RHI`BP92@!.1!DM8#]2M(
M""85-*^`80W^CZC\`2X)!TKO5S"&`5#0N<N=WB[YLRJDT-AN7UQ1-AAWH91C
M4"`8QQ<)6*5#8/*7I)EVH.-[U7PI'"VOLT3%>9[Q^_!]HKB26D')(2S*"!1!
MH(?;3L(8F'$AVYC:-E`,06.FQ75+/8,DYCI-#,HRB=1MQP4-$L=2]:%KL#RK
M08>`C5VKYQ6-&B3(*E"E2#H%KS2VP1E%`!@X_<3ZG6X5##TG#.J?VY`O@*FE
MZ>T,:KLC9S'9,C\NHVA098:,A5"<3^JRM`)SOE33'T'<JZ/<Z55.<XNXJ"(V
M1C8]?J8P01$06RQQC8S,J'LF.+*BU<444Y"+L9L87-;1@BR&IWMI7$H!B%9T
M[_G$@>RFLL_5>R47^6T0H1OHD((TS0DMPG-]H5E5LG3-7`8:<]!`I`MKB`J[
M<FE2`%2!<$F[2N'#D\`"'V=R*)I0-^<G/&[=RRR[,ZF#J*^3EM.6.CC'8K5J
M<Z'W8.1,R`+;W7(ZD.[5U]&VX#;H4/5%3N7D+NC[7C,I<6&U8T+BWC(MF?-]
M\.$O^QP*XUN<43M_DEEXF+I<0LP$WB<JEK='!M\G;(BSC6S-5P;S%.WTF)(R
M@\>1>A0'F,U'&6OO%`GQ#V<<)#5#3_GSVZ0$29AGCQ7.GQ$U)Q00G@(@&DV7
M<+62MMB15F"5@MT@@*YUYC`E!JO&@1H#(*FB6\\%*/-1%+&-*PBAD2P3I15]
M:`$`N;@$8I[#F9HVY`RZ/W6-",R%G@J/\;0[?83L(`QN>UM2)ZT$3V6[^!JK
M6+&%5WC#U+#HRDOV=.7S`-TUX"(^R$_^9>2+UTE8X5%A)I=*TGY@,$Q._4&#
M,546(^%+BSLD8`T*8:`VLK+J3M`"!)H/=9FH*!+XI'^X!1H@!J?UJK5"H!G"
M*,J,Q!;!6MP9J8[6,+04HJ#0WEVN)OOGT\Z;AAI"S2F46<X?!]/(6Q(HU8/C
M63,O$FU^0(2D,HRS&X!<VQ=E;)VG*S`+V-\.<0Z`-.`,@\B.$C72WC7=?FOO
M<Q;&LT9JQ@#`]^C1.^Y-6%IY*L-J2RX8UF6HW,]O&KX&A2D)JN@BC7:%V4)%
MT4W_``KH1PPIL0+]E5\0+43%B&3>,2R!:(<[+@P*A'QJ?R\"H!*R6=FFP&GS
MA48&!C4EA=P<&G;C.,.&(PF.)@<";A.=,@G@L.H88+?D/B')(PZ$!/XU-MSD
M%V-9+;`:I&$=<[@R^0%E`W%7ZFLRF=B(+>.PZ=JK2Q(C@+8$=HHQ`D$$+CE^
M;,*Y34N;Q/S[`W)GB5"H3.WBT-W++B;0<-["V:SW`"I#PWT7BH575ZC^+O)T
M?&+'3T<VUR<%-3'80W2*`PG,R.EL;5+DU9WLOR`%!Q(O!%V1N._6@X;-2*-8
MU.;2U'+>O?'RN>&B),77)?6M!U6T!3)=ED;$)_H`,]#[`^R'Q[D0`."("C_A
MR@,RPL4B`N"//G$@LB''*"!N@(8=&O*T5S-9M&WFC?DD^^:`"6@`&D!/7]#C
M@CH?`BYL"_DY!009ML,FIG9*?/$L<U=6?D--O2$JJN:`.S-`@8>QO>*",T1%
MQ$B)RI@+<&].-H#0QNY_N[+_`"D:/5H/;KYEPR[K&G"K^#4^MO+J01PL"1$!
M!IT`]4OG%)K_`(JTTK%()M_H(B-Z_="4\=P)@R`0!";Z#J1K*>[*9CEY+J6Z
M,=W;D=R1K#RK#^FK<%)KO^SGVG?UU__:``@!`@,!/Q#ZR=YJ/I--V^BWN4\R
M@L[EPP)^;0XV;:-X9U7_`,Q39EYO+^!_?T2,SX]3D^<<7YZR33Z_W]*BQ2`#
M:'H;97P+@Y4U$@%G$#<X>[K$%\PQN<*1DI1AM>71-LB:#>.H#0FQ$`D\1Q@I
MDQ4A0E("K&]*XP=)-"W@Q.$MD'<P+?C(R]8'*=?4"L,`@/.$[]`5AZ&]8+T1
MLU#;%:`"VUA4*@H."C[%!?E#%_!P1BR(RP'%]KD$5K'DVJ2@E'):]#9[,%TE
M826=4^E;MS^XP1H]$CKK%7G/YYR_.<V%FN/DS^65M[Q?NPS3R,4P%NAI`%LP
MS'95(-D;'L#BX$M0>$0H>11?(ISEQ"!%W=%I98`O.<;G3%N;6UA:12D(-;R5
MV"^`JC)INM8Q`8VR".ZL7<\*P"0(?9!R^'>=<L`[9KK%.G/Y.%:]YPP0!,5>
M<T]R8HUP8(PQO']V:GOFY#_/H57TV7X0LCR`'A@&Z9#%31C*A9!0[,.<V?<_
M;#MZ[6_E"_OB=!\'J.5<UNDAMWA'F(BIM@!$@'I$",55<FI^=9(65WJE<-"W
MS?;'YR*E'`O(QB:T^/5@<X//QC;'TY;KT&-QB)QB&NL6MQ5YRDASZ#$J2D+0
MB'`(@B4$V^H2CNE"K!2&@3!2<0PD$)T*I=BJYHK($!=H!RN.I<,M4284`O>`
M.UV&$)\)H:!WH"@`3:LB"-E/,(@71&O$H%D>0"P`4$'<4]_6D3],4>/+BEUK
M+-\OVQ=!Z(H=#^V7>]X/(]%K7%L[]1#I3XR4`@1D"`00``#@XPB-&B6Y:H(H
M`JJO#.W1<3GB/>E`#:J"4.JA=OY?'H*X*0,[.-AUUGY#J_#[Z]?0>?15I_0I
MZK=O],.<>?K_`/_:``@!`P,!/Q#\`:7Z6]>FL>"<6"S$HCO3`5":B>2]S_SH
M.?''X1OZ>'XPDUQ]+H9N!2O`#M=%AY3$8>(!5!0H?'V8A<XSY1](.8,57>ON
M;Q;^LDP@8\CI&BF`V"1`$H,06,E>0R9'92T(*;?8-;>/19E+.\7]_J6<XL+G
MQ]*X0Z`*Z*!`I4T:K!6DSRS^\;^@XL5`91"F0O*^9[S-"/`H1U(*!$+P)OT2
MB=XQ:(5$A?;ZX._IX9PS3\^D).O11\CR$^7AJMNG)<7X\J@773$NAY,9D;3O
M3`G#37O[807Y8C20A0*VJ=9SP'E#0'6C&Z#&\Y#G'0!1O30%;.&]X^NGP&NF
MCD8'!6&(C4;W)\=WT;UZ'\8P(\8>W&%;Z'%ZR'.75R^AG?'HS``FJ.1ER<($
M?)K`M>0G3+MLLW.P?&/*TZXXZ[XQ_G6&1YNG9T-":V[=<8AI,T=6I51$&SLB
M([2D<,_G_>'R%30`P^:R>)@Y)16E.1\)K3O9Z[OM]!)KCU"$<"'TV;=*6F4%
M%(-B*!+$3%L`Z6-32\VAC=JYR'*.U!,/*K#1H``Q0=C6JA14X'/>/3H"4*E"
M(]PF@U<36R\^NUV0JHP54:`"9+Q)Q2`$1K5#EIX$`JD!2@S6J'QZS=P&_;"]
M_0$)D\8E]4NO6>8F.U`JV:M7:VO*Y#;EIUI`5HU5((1YSKW_`)>L]SRE-BM&
D0V3/?6:?D7^,&&32L?"#?>?GQQ\_KMW[?4$)_P#([G_/P/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
